Chemoradiotherapy in the management of localized tumors of the pancreas

Annals of Surgical Oncology

Volumn 6, Issue 1, 1999, Pages 117-122

  Poen, Joseph C ^a,d   Ford, James M ^b   Niederhuber, John E ^c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Malignant neoplasm; Pancreas; Radiotherapy

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; TOPOTECAN;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DNA SYNTHESIS INHIBITION; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PANCREATICODUODENECTOMY; TUMOR LOCALIZATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT;

EID: 0033056887     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0117-1     Document Type: Conference Paper

References (21)

1. Douglass HO Jr. Adjuvant therapy for pancreatic cancer. World J Surg 1995;19:270-4.
2. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg 1997;225:621-33.
3. Poen JC, Collins HL, Niederhuber JE, et al. Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion of 5-fluorouracil. Int J Radiat Oncol Biol Phys 1998;40:93-9.
4. Bunis HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
5. Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreaticoduodenectomy for carcinoma of the pancreatic head. Br J Surg 1994;81:1642-6.
6. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-37.
7. Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161-7.
8. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317-23.
9. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
10. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combinedmodality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
11. 125I Interstitial implant, precision high-dose external beam therapy and 5-FU for unresectable adenocarcinoma of pancreas and extrahezpatic biliary tree. Cancer 1986;58:2185-95.
12. Mohiuddin M, Rosato F, Barbot D, Schuricht A, Biermann W, Cantor R. Long-term results of combined modality treatment with 1-125 implantation for carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1992;23:305-11.
13. Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation of locally advanced pancreatic cancer. Cancer 1988;61:1110-6.
14. Mohiuddin M, Regine WF, Stevens J, et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995;13:2764-8.
15. Rougier P, De Forni M, Adenis A, et al. Phase II study of Taxotere (RP56976) in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1994;13:200.
16. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-50.
17. Safran H, King T, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol 1997;15:901-7.
18. Abbruzzese JL, Levin B, Ajani JA, et al. A phase I trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal cancer. Cancer Res 1989;49:4057-61.
19. Gibbs JB, Oliff A, Kohl NE. Famesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.
20. Gjertsen MK, Bakka A, Frievik J, et al. Ex vivo Ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;65:450-3.
21. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy. Phannacol Ther 1997;75:69-75.